Examiner-Initiated Interview Summary	Application No.	Applicant(s)
	10/591,252	KAWAGUCHI ET AL.
	Examiner	Art Unit
	D L. Jones	1618
All Participants: Status of Application: <u>071</u>		
(1) <u>D L. Jones</u> .	(3)	
(2) <u>Jerrick Ho</u> .	(4)	
Date of Interview: <u>30 July 2010</u>	Time:	
Type of Interview: ☐ Telephonic ☐ Video Conference ☐ Personal (Copy given to: ☐ Applicant ☐ Applicant's representative) Exhibit Shown or Demonstrated: ☐ Yes ☐ No If Yes, provide a brief description:		
Part I.		
Rejection(s) discussed: n/a		
Claims discussed: all pending claims		
Prior art documents discussed: n/a		
Part II.		
SUBSTANCE OF INTERVIEW DESCRIBING THE GENERAL NATURE OF WHAT WAS DISCUSSED: See Continuation Sheet		
Part III.		
 It is not necessary for applicant to provide a separate directly resulted in the allowance of the application. The of the interview in the Notice of Allowability. It is not necessary for applicant to provide a separate did not result in resolution of all issues. A brief summa 	ne examiner will provide a written record of the substance of the	en summary of the substance interview, since the interview
/D L. Jones/ 7/30/10 Primary Examiner, Art Unit 1618	Applicant/Applicant's Representat	ive Signature – if appropriate)

Continuation of Substance of Interview including description of the general nature of what was discussed: The Attorney and Examiner discussed the application and changes to place the case in condition for allowance. The Examiner was given authorization to make the following changes.

Replace claim 4 with the following.

- 4. (Currently Amended) The medical composition according to claim 1, wherein the basic amino acid is at least one selected from the group consisting of arginine, histidine, and lysine.

 Replace claim 6 with the following.
- 5. (Currently Amended) A diagnostic or therapeutic pharmaceutical comprising the medical composition of claim 1 and a pharmacologically acceptable additive.

Cancel claim 7.

Cancel claim 8.

Replace claim 15 with the following.

15. (Currently Amended) The composition of claim 1 in freeze-dried form.

Cancel claim 16.

Replace claim 17 with the following.

17. (Currently Amended) The medical preparation according to claim 1 wherein the metal is a radioactive metal or paramagnetic metal.

Replace claim 20 with the following.

20. (Currently Amended) A method for labeling a peptide with a metal wherein the peptide is selected from the group consisting of N-formyl-Nle-Leu-Phe-Nle-Tyr-Lys(NH2)-ε(-Ser-Cys-Gly-Asn) (SEQ ID NO: 1), N-formyl-Nle-Leu-Phe-Nle-Tyr-Lys(NH2)-ε(-Ser-Cys-Gly-Asp) (SEQ ID NO: 2), N-formyl-Nle-Leu-Phe-Nle-Tyr-Lys-ε(-Ser-Cys-Asp-Asp) (SEQ ID NO: 3), N-formyl-Nle-Leu-Phe-Nle-Tyr-Lys(NH2)-ε(-Ser-D-Arg-Asp-Cys-Asp-Asp) (SEQ ID NO: 4), N-formyl-Nle-Leu-Phe-Nle-Tyr-Lys(NH2)-ε(-Ser-D-Arg-diethylenetriaminepenaacetic acid (DTPA)) (SEQ ID NO: 5), N-formyl-Met-Leu-Phe-Lys-ε(-Asp-Asp-mercaptoacetyl) (SEQ ID NO: 7), N-formyl-Met-Leu-Phe-Lys-ε(-Gly-Asp-mercaptoacetyl) (SEQ ID NO: 8), and N-formyl-Met-Leu-Phe-Lys-ε(-Gly-Gly-mercaptoacetyl) (SEQ ID NO: 9), comprising the steps of: dissolving the peptide in an aqueous solvent of a basic organic compound; and then labeling the resulting product with a metal.

Replace claim 21 with the following.

21. (Currently Amended) The method according to claim 20, wherein the peptide labeled with a metal is insoluble or poorly soluble in an aqueous solvent.

Replace claim 22 with the following.

22. (Currently Amended) The method according to claim 20, wherein the basic organic compound is a basic amino acid or a basic compound having an imidazole ring.

Replace claim 23 with the following.

23. (Currently Amended) The method according to claim 22, wherein the basic amino acid is selected from the group consisting of arginine, histidine, and lysine.

Replace claim 24 with the following.

24. (Currently Amended) The method according to claim 22, wherein the basic compound having an imidazole ring imidazole.

Replace claim 25 with the following.

25. (Currently Amended) The method according to claim 20, wherein the metal is a radioactive metal or paramagnetic metal.

Replace claim 26 with the following.

26. (Currently Amended) The method according to claim 25, wherein the radioactive metal is selected from Tc-99m, In-111, Ga-67, Y-90, Sn-117m, Sm-153, Re-186, and Re-188.

Replace claim 27 with the following.

27. (Currently Amended) The method according to claim 25, wherein the paramagnetic metal is selected from Gd, Fe, Mn, Cu, and Dy.

Cancel claim 28. Replace claim 4 with the following.

4. (Currently Amended) The medical composition according to claim 1, wherein the basic amino acid is at least one selected from the group consisting of arginine, histidine, and lysine.

Replace claim 6 with the following.

5. (Currently Amended) A diagnostic or therapeutic pharmaceutical comprising the medical composition of claim 1 and a pharmacologically acceptable additive.

Cancel claim 7.

Cancel claim 8.

Replace claim 15 with the following.

15. (Currently Amended) The composition of claim 1 in freeze-dried form.

Cancel claim 16.

Replace claim 17 with the following.

17. (Currently Amended) The medical preparation according to claim 1 wherein the metal is a radioactive metal or paramagnetic metal.

Replace claim 20 with the following.

20. (Currently Amended) A method for labeling a peptide with a metal wherein the peptide is selected from the group consisting of N-formyl-Nle-Leu-Phe-Nle-Tyr-Lys(NH2)-ε(-Ser-Cys-Gly-Asn) (SEQ ID NO: 1), N-formyl-Nle-Leu-Phe-Nle-Tyr-Lys(NH2)-ε(-Ser-Cys-Gly-Asp) (SEQ ID NO: 2), N-formyl-Nle-Leu-Phe-Nle-Tyr-Lys-ε(-Ser-Cys-Asp-Asp) (SEQ ID NO: 3), N-formyl-Nle-Leu-Phe-Nle-Tyr-Lys(NH2)-ε(-Ser-D-Arg-Asp-Cys-Asp-Asp) (SEQ ID NO: 4), N-formyl-Nle-Leu-Phe-Nle-Tyr-Lys(NH2)-ε(-Ser-D-Arg-diethylenetriaminepenaacetic acid (DTPA)) (SEQ ID NO: 5), N-formyl-Met-Leu-Phe-Lys-ε(-Asp-Asp-mercaptoacetyl) (SEQ ID NO: 7), N-formyl-Met-Leu-Phe-Lys-ε(-Gly-Asp-mercaptoacetyl) (SEQ ID NO: 8), and N-formyl-Met-Leu-Phe-Lys-ε(-Gly-Gly-mercaptoacetyl) (SEQ ID NO: 9), comprising the steps of: dissolving the peptide in an aqueous solvent of a basic organic compound; and then labeling the resulting product with a metal.

Replace claim 21 with the following.

21. (Currently Amended) The method according to claim 20, wherein the peptide labeled with a metal is insoluble or poorly soluble in an aqueous solvent.

Replace claim 22 with the following.

22. (Currently Amended) The method according to claim 20, wherein the basic organic compound is a basic amino acid or a basic compound having an imidazole ring.

Replace claim 23 with the following.

23. (Currently Amended) The method according to claim 22, wherein the basic amino acid is selected from the group consisting of arginine, histidine, and lysine.

Replace claim 24 with the following.

24. (Currently Amended) The method according to claim 22, wherein the basic compound having an imidazole ring imidazole.

Replace claim 25 with the following.

25. (Currently Amended) The method according to claim 20, wherein the metal is a radioactive metal or paramagnetic metal.

Replace claim 26 with the following.

26. (Currently Amended) The method according to claim 25, wherein the radioactive metal is selected from Tc-99m, In-111, Ga-67, Y-90, Sn-117m, Sm-153, Re-186, and Re-188. Replace claim 27 with the following.

27. (Currently Amended) The method according to claim 25, wherein the paramagnetic metal is selected from Gd, Fe. Mn. Cu. and Dv.

Cancel claim 28.

/D. Jones/ 7/30/10 Primary Examiner Art Unit 1618